This anti-inflammatory function has benefits in the central nervous system as well (Diz-Chaves et al., 2022), and GLP-1 receptor agonists have been shown to be neuroprotective in animal models of Alzheimer’s disease (Perry and Greig, 2002; Reich and Holscher, 2022; Holscher, 2022a; Perry et al., 2023), Parkinson’s disease (Aviles-Olmos et al., 2013; Feng et al., 2018; Reich and Holscher, 2022; Holscher, 2022b), epilepsy (Wang et al., 2018), and stroke (Li et al., 2009; Teramoto et al., 2011). The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.